



Cyclacel Pharmaceuticals, Inc.  
Investor Relations Department  
200 Connell Drive, Suite 1500  
Berkeley Heights, NJ 07922  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

**NASDAQ: CYCC <sup>1</sup>**

Last Trade:	1.74
Trade Time:	4:00 PM ET Nov 17, 2017
Change:	-0.04  (1.972%)
Day Range	1.70 - 1.80
52-Week Range	1.50 - 10.90
Volume	220,010
Market Cap. (\$M)	20.706
Shares Out (M)	11.900

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

We are a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Our strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Nov 9, 2017  
[Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results](#)
- Nov 2, 2017  
[Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results](#)
- Nov 1, 2017  
[Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting](#)
- Sep 21, 2017  
[Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference](#)
- Sep 8, 2017  
[Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

- Mar 31, 2017  
[Annual Report \(10-K\)](#)
- Apr 12, 2017  
[Definitive Proxy Statement](#)
- Nov 13, 2017  
[Quarterly Report \(10-Q\)](#)
- Aug 10, 2017  
[Quarterly Report \(10-Q\)](#)
- May 12, 2017  
[Quarterly Report \(10-Q\)](#)